Search results for: Value-Based Pricing
Filter search results
Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
1 May 2019
…providing new medicines that provide improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a better value for money. In this short…
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
…work for payers with a fixed budget? If the rewards are linked to value, how would the budget impact on payers differ from Value-Based Pricing? Might retroactive adjustment be needed?…
The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot
12 October 2022
…value assessment of antibiotics? The pilot exposed the opportunities and challenges that lay ahead for the value assessment of antibiotics. All stakeholders should focus on improving the underlying value assessment…
Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?
17 September 2020
…a framework consisting of ten value elements to measure the ‘broader value of vaccination’. Table 1 below illustrates that, to date, only five out of these ten value elements are…
Value Based Pricing in Sweden: Lessons for Design?
28 November 2012
OHE has just published a Seminar Briefing by Ulf Persson, head of the Swedish Institute of Health Economics, which reviews experience with the Swedish value based pricing (VBP) system. Prof…
Changes in Determining Medicines Pricing in France, Germany and the UK
24 January 2013
…the emphasis of the recent reforms is centred around evidence requirements and, in particular, the choice of comparators and the use of head-to-head trials. In the UK, however, value-based pricing…
Are Cost-Effectiveness Thresholds Fit for Purpose for Real-World Decision Making on Access to and Pricing of Pharmaceuticals? A New OHE Paper on Current Methods and Practices, and a Novel Approach for Optimal Thresholds
3 March 2020
…OHE Research Paper. Available at https://www.ohe.org/publication s/case-risperidone-assessing-life-cycle-value-second-generation-antipsychotics-sweden-and Pandey, H., 2018. Theoretical models of the cost-effectiveness threshold, value assessment, and health care system sustainability. Institute of Health Economics. Available at https://www.ihe.ca/publications/theoretical-models-of-the-cost-effectiveness-threshold-value-assessment-and-health-care-system-sustainability…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
…A. & Zamora, B., 2019. Indication-Based Pricing (IBP) Discussion Paper. OHE Briefing, London: Office of Health Economics. Available at: https://www.ohe.org/publications/indication-based-pricing-ibp-discussion-paper-should-drug-prices-differ-indication Lakdawalla, D., MacEwan, J.P., Dubois, R., Westrich, K., Berdud,…
OHE Launches Discussion Paper and Consultation Exercise on Indication-based Pricing
10 May 2019
Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better…